Prime Medicine (Prime Medicine) Total Receivables : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Total Receivables?

Prime Medicine's Total Receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Prime Medicine Total Receivables Historical Data

The historical data trend for Prime Medicine's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine Total Receivables Chart

Prime Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Receivables

Prime Medicine Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Receivables	Get a 7-Day Free Trial									-	-	-	-	-

Prime Medicine Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Prime Medicine Total Receivables Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Prime Medicine (Prime Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Erie Street, Cambridge, MA, USA, 02139

Website

https://www.primemedicine.com

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Executives

Gv 2019 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Robert Nelsen	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Thomas Cahill	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Arch Venture Partners X, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson	officer: See Remarks	88 SIDNEY STREET, CAMBRIDGE MA 02139
Keith Crandell	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kaye I Foster-cheek	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Meredith Goldwasser	officer: SVP, Strategy & Corporate Ops.	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139